一、2024 年度向特定对象发行 A 股股票的基本情况 2024 年 8 月 12 日召开第二届董事会第二十五次会议、第二届监事会第二十 四次会议，审议通过了《关于公司 2024 年度向特定对象发行 A 股股票方案的议 案》等相关议案，同意公司拟向傅和亮先生发行不超过 14,534,883 股（含本数） 股份，募集资金总额不超过 10,000.00 万元（含本数），扣除相关发行费用后的 募集资金净额全部拟用于补充流动资金，以下简称"前次定增事项"。 证券代码：688488 证券简称：艾迪药业 公告编号：2026-010 江苏艾迪药业集团股份有限公司 关于终止公司 2024 年度向特定对象发行 A 股股票的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于 2026 年 1 月 13 日召开第三届董事会第十一次会议，审议通过了《关于终止公司 2024 年度向特 定对象发行 A 股股票事项的议案》等相关议案，公司决定终止 2024 年度向特定 对象发行 A 股股票事项，本 ...

基于总体工作安排，公司董事会拟暂不召开股东会。公司将根据总体工作安 排及实际情况适时召开股东会审议相关议案，并另行发布召开股东会的通知。 特此公告。 证券代码：688488 证券简称：艾迪药业 公告编号：2026-003 江苏艾迪药业集团股份有限公司董事会 2026 年 1 月 14 日 江苏艾迪药业集团股份有限公司 关于暂不召开股东会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于 2026 年 1 月 13 日召开第三届董事会第十一次会议，审议通过了《关于前次募集资金使用情况专 项报告的议案》《关于公司 2026 年度以简易程序向特定对象发行 A 股股票摊薄 即期回报及采取填补措施和相关主体承诺的议案》《关于公司未来三年 （2025-2027 年）股东分红回报规划的议案》，上述议案尚需公司股东会审议。 具体内容详见公司于本公告同日在上海证券交易所网站（www.sse.com.cn）发布 的相关公告。 1 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

与会董事就如下议案进行了审议，并表决通过以下事项： 证券代码：688488 证券简称：艾迪药业 公告编号：2026-002 江苏艾迪药业集团股份有限公司 第三届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届董事会第十次 会议通知于 2025 年 12 月 27 日送达全体董事，会议于 2025 年 12 月 31 日在公司 会议室以现场结合通讯表决方式召开。本次会议由董事长傅和亮先生主持，应到 董事 9 名，实到董事 9 名。本次会议的召集和召开程序符合《中华人民共和国公 司法》和《公司章程》等相关规定。 二、董事会会议审议情况 同时，董事会授权董事长或总裁及其授权代表在上述授信额度内办理相关手 续，并签署上述授信额度内一切与授信有关的合同、协议等各项法律文件，授权 公司财务部门根据公司的资金需求情况，分批次向银行、信托、其他金融机构为 公司办理有关授信融资借款等手续。上述授权有效期自公司本次董事会审议通过 之日起至 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2026-001 江苏艾迪药业集团股份有限公司 关于公司 2026 年度日常关联交易额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否。 日常关联交易对上市公司的影响：本次预计的关联交易属公司日常关联 交易，为公司正常生产经营业务，是以公允定价为原则，结合市场价格进行的定 价，定价合理、公允，不影响公司的独立性，不存在损害公司和全体股东利益的 情形。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 江苏艾迪药业集团股份有限公司（以下简称"公司"或"艾迪药业"）于 2025 年 12 月 31 日召开了第三届董事会第十次会议，审议通过了《关于公司 2026 年 度日常关联交易额度预计的议案》，2026 年度日常关联交易预计金额合计为 2,015.45 万元，关联董事均回避表决，出席会议的非关联董事一致同意该议案， 审议程序符合相关法律法规的规定。本次日常关联交易额度预计事项在公司董事 会决策权限范围内，无 ...

格隆汇12月24日丨艾迪药业(688488.SH)在互动平台表示，出海是公司重要的发展战略之一，公司目前 出口业务量在公司整体营收中占比较小。公司将持续深化海外市场多元化开拓，培育新增长点，提升国 际竞争力。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002880 | 卫光生物 | 25.31 | -1.02% | 7083.18 | 1790.31万 | | 002252 | 十件與上 | 6.36 | -0.47% | 26.50万 | 1.68亿 | | 301393 | 吴帆生物 | 49.17 | -0.45% | 1.01万 | 4922.42万 | | 688670 | 金迪克 | 22.19 | -0.31% | 4.31万 | 9611.75万 | | 301080 | 百普赛斯 | 52.13 | -0.29% | 2.41万 | 1.24亿 | | 000661 | 长春高新 | 95.31 | -0.23% | 7.81万 | 7.35亿 | | 300239 | 东宝生物 | 5.27 | -0.19% | 9.38万 | 4908.25万 | | 300318 | 博晖创新 | 6.24 | -0.16% | 10.33万 | 6417.65万 | | 688105 ...

Core Points - The National Healthcare Security Administration announced the 2025 National Medical Insurance Drug List, which will take effect on January 1, 2026, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by better alternatives [2][4] Group 1: Drug List Adjustments - The total number of drugs in the directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2][4] - The 2025 adjustment marks the 8th update since the establishment of the National Healthcare Security Administration [7] Group 2: Company Announcements - 15 A-share pharmaceutical companies announced that their products have been included in the new directory, with many innovative drug companies benefiting from this inclusion [4] - Zai Lab's drug, Jikaxitinib, has been included in the directory, which is expected to enhance sales and improve patient accessibility [4] - Junshi Biosciences reported that its products, including Toripalimab and an additional indication for another drug, have been successfully included in the directory [4] - Innovent Biologics' drug, IBI301, has also been added to the new directory, marking a significant milestone for the company [5] - Leading A-share pharmaceutical companies like Fosun Pharma, East China Pharmaceutical, and Heng Rui Medicine have also had several products included, with Heng Rui reporting a combined sales figure of approximately 8.66 billion yuan for the newly added drugs in 2024 [6][7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 根据国家医疗保障局网站于2025年12月7日发布的《国家医保局人力资源社会保障部关于印发〈国家基 本医疗保险、生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉（2025年）的通知》 （医保发〔2025〕33号），江苏艾迪药业集团股份有限公司（以下简称"公司"）两款抗艾滋病领域国家 1类新药一一艾诺韦林片（商品名：艾邦德?）及艾诺米替片（商品名：复邦德?）通过了医保谈判，以 简易续约方式继续纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（以下简 称"《国家医保目录》（2025年）"）。现将具体情况公告如下： 一、药品基本情况 三、对公司的影响 公司两款抗HIV领域创新药原价续约进入《国家医保目录》（2025年），既体现了国家医疗保障局对两 款创新药在临床价值、患者获益及产品创新性等方面的肯定，也体现了国家对具有临床价值创新产品的 支持；患者将能够通过医保报销获得药物治疗，有利于提升该产品于患者的可负担性和可及性，有利于 进一步推动上述药物的销售及 ...

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]